Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2293
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-28T06:45:56.995058Z
status: published
lens: p_space
sector: health
headline: When machines estimate kidney function and predict risk: Clinical applications of machine learning
dek: The use of artificial intelligence, and particularly machine learning, is rapidly expanding in medicine. In nephrology, these approaches have generated growing interest owing to the availability of large clinical, biological, and administrative datasets, as well as the need for more accurate assessment of kidney function and changes over time. Two major areas of application have emerged: estimation of glomerular filtration rate (GFR) and prediction of chronic kidney disease (CKD) progression. Initial studies foc…
gain_title: (none)
problem_title: Large multicenter studies show machine learning improves kidney function estimation only marginally over EKFC or CKD-EPI, and few risk models clearly beat the Kidney Failure Risk Equation.
trace_subject: (none)
gain_reading: (none)
gain_evidence: (none)
problem_reading: Large multicenter studies show machine learning improves kidney function estimation only marginally over EKFC or CKD-EPI, and few risk models clearly beat the Kidney Failure Risk Equation.
problem_evidence: machine learning provides only marginal improvements over modern equations such as EKFC or CKD-EPI
quick_read: A review in Néphrologie & Thérapeutique examines two uses of machine learning in kidney care: estimating glomerular filtration rate (GFR) and predicting how chronic kidney disease progresses. Early studies using neural networks, random forests and ensemble methods looked encouraging for GFR estimation.

Recent large multicenter work suggests the bottleneck is the biomarkers available rather than the algorithms, so smarter models do not fix weak inputs. Progression prediction looks more promising, but proof of clinical advantage over established tools remains limited, and routine use in nephrology is still a future direction.
limitation: Only a limited number of progression models have shown a clear clinical advantage over established tools such as KFRE, so the practical value of machine learning in nephrology remains unproven.
tag: Evidence-backed problem
key_points: GFR estimation with machine learning gives only marginal improvement over EKFC or CKD-EPI when the same variables are used. | Limits in GFR estimation are attributed to available biomarker information rather than algorithm capacity. | Machine learning appears well suited to predicting kidney disease progression by integrating many clinical and laboratory variables. | Few progression models have shown a clear clinical advantage over the Kidney Failure Risk Equation.
rundown: The review covers supervised learning approaches such as artificial neural networks, random forests and ensemble methods applied to GFR estimation, motivated by large clinical, biological and administrative datasets and the need to track kidney function over time.

For progression, the models combine numerous clinical and laboratory variables to flag patients at high risk of rapid decline or kidney failure. The authors compare them with the Kidney Failure Risk Equation as the established benchmark.

The paper also discusses strengths, limitations and future directions for integrating these tools into nephrology practice.
sources:
- peer_reviewed | Néphrologie & Thérapeutique | https://doi.org/10.1684/ndt.2026.205 | 2026-10-27
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

520e1398144e6f8aba582d4a5636b022e63ba6f1898ee8722dcd3c1112a14664

previous

0000000000000000000000000000000000000000000000000000000000000000